

Prescribing in Chronic Obstructive Pulmonary Disease (COPD)

Laura Leeks Specialist Respiratory Physiotherapy Non medical prescriber Camden COPD and Home Oxygen Service





Aims


- RPS (2020) Competency framework for prescribers
- Guidelines
 - NICE (Updated 2019)
 - GOLD (2021)
- Assessment / Diagnosis
- Management of stable COPD
- Management of acute exacerbations





Guidelines

GOLD (2021)



https://goldcopd.org/wpcontent/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20 WMV.pdf

NICE (2018, Update 2019)

NICE National Institute for Health and Care Excellence



Chronic obstructive pulmonary disease in over 16s: diagnosis and management

NICE guideline Published: 5 December 2018 www.nice.org.uk/guidance/ng115

https://www.nice.org.uk/guidance/ng115/r esources/chronic-obstructive-pulmonarydisease-in-over-16s-diagnosis-andmanagement-pdf-66141600098245




COPD Definition



COPD, a common preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation that is due to airway and /or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.

GOLD 2021 (www.goldcopd.org)







When to suspect COPD



- Smokers or ex-smokers (including cannabis) over 35 with a 10 year history of smoking or greater who have any symptoms of COPD:
 - Exertional breathlessness
 - Chronic cough
 - Regular sputum production
 - o Frequent winter 'bronchitis'
 - Wheeze
- No signs of asthma
 - Significantly variable breathlessness
 - Night-time wakening with breathlessness and/or wheeze
 - Significant diurnal or day-to-day variability of symptoms.



Spirometry




- Post-bronchodilator FEV1 / FVC < 0.7
 <p>FEV1 (Forced Expiratory Volume in one second)
 FVC (Forced Vital Capacity)
- Bronchodilation:
 - Nebulised 2.5mg 5mg salbutamol.
 - Inhaled via pMDI and disposable spacer 4 puffs x 100 micrograms salbutamol.
 - \circ Measure lung function 15 minutes after β 2-agonist.

FEV1 % predicted	Severity of airflow obstruction
≥ 80%	Stage 1 - Mild
50-79%	Stage 2 - Moderate
30-49%	Stage 3 - Severe
<30%	Stage 4 - Very Severe





Volume time curve







Goals of COPD assessment:

Symptom burden

• COPD Assessment Test (CAT) 0-40

MRC D	MRC DYSPNOEA SCALE (for COPD patients)			
Grade	Impact			
1	Not troubled by breathlessness except on vigorous exertion			
2	Short of breath when hurrying or walking up inclines			
3	Walks slower than contemporaries because of breathlessness, or has to stop for breath when walking at own pace			
4	Stops for breath after walking about 100 m or stops after a few minutes' walking on the level			
5	Too breathless to leave the house or breathless on dressing or undressing			

• Exacerbation risk

- Frequent = 2 or more per year or 1 requiring hospital admission
- $\circ~$ No. of exacerbations in previous year
- Declining airflow obstruction
- Comorbidities





GOLD classification

≥2 exacerbations or 1 requiring hospital	C High risk, less symptoms	D High risk, more symptoms
0-1 exacerbation	A Low risk, less symptoms	B Low risk, more symptoms
	mMRC 0-1 CAT < 10	mMRC2-4 CAT > 10

Symptom burden



Exacerbation risk

Other Investigations



Investigation	Role
CXR CT scan	Rule out other pathologies Investigate symptoms disproportionate to spirometry, suitability for LVR surgery
Full blood count Hb, Hct, Eosinophil count	Anaemia, polycythaemia, eosinophilia
BMI	Nutritional status, prognostic factor
Serial PEFR	Exclude asthma
ECG Serum natriuretic peptides ECHO	If cardiac disease / pulmonary hypertension suspected
Alpha-1 Antitrypsin	If early onset, minimal smoking history, family history
Transfer Factor for carbon monoxide (TLCO)	Investigate symptoms disproportionate to spirometry
Pulse oximetry	To assess need for oxygen therapy, if cyanosis or cor pulmonale present or FEV1 < 50%
Sputum Culture	To identify organisms if sputum is persistently present and purulent or frequent exacerbator



Differential diagnosis

- Further investigation required:
 - Copious / purulent sputum
 - Restriction on spirometry

Red flags

- Haemoptysis
- Clubbing
- Weight loss
- Night sweats





Management of Stable COPD


Aims:

- Reduce symptoms
- Reduce frequency and severity of exacerbations
- Improve exercise tolerance
- Improve health status






London Respiratory Network "Value Pyramid"





COPD Risk and Smoking Cessation



National centre for smoking cessation and training

https://www.ncsct.co.uk/publication_very-brief-advice.php

• Smoking is an enzyme inducer (CYP1A2)







Pulmonary rehabilitation

- Offer to every patient with:
 - Confirmed COPD diagnosis
 - BREATHLESSNESS MRC≥3
 - Hospital admission for COPD or frequent exacerbations irrespective of MRC score, provided COPD diagnosis confirmed).
- If MRC score 1 or 2 offer EXERCISE ON REFERRAL and local LIFESTYLE EDUCATION program.
- <u>https://www.blf.org.uk/support-for-you/keep-active/pulmonary-rehabilitation</u>





Inhaled therapy options for COPD

- Bronchodilators:
 - Beta 2 agonists (Short Acting SABA / Long Acting LABA)
 - Muscarinic antagonists (SAMA / LAMA)
- Inhaled corticosteroids (ICS)
- Combinations
 - LABA / LAMA
 - ICS / LABA
 - ICS / LABA / LAMA (triple therapy)



Inhaled therapy guide



Step 1 – MILD – Few symptoms, ≤1 exacerbation / year

• PRN SABA / SAMA

Step 2 – MODERATE – MRC 2, ≤1 exacerbation / year

- Regular LAMA or LABA
- Continue SABA, Stop SAMA

Step 3 – SEVERE – MRC 3 and /or ≥ 2 exacerbations / year

- Regular LAMA / LABA combination
- Or Regular ICS / LABA combination (if concomitant asthma)


Step 4 – VERY SEVERE – Progressive breathlessness or ongoing exacerbations

- "Triple therapy"
- ICS / LABA / LAMA combination





Bronchodilators – Mechanism of action







Beta 2 agonists

Short acting (SABA)	Long acting (LABA)
Salbutamol 100mcg 2 doses Four times daily	Salmeterol 25mcg (Serevent®) 2 doses Twice daily
Entation	AeroChamber





Beta₂-adrenoceptor – Sympathetic

Bind to beta₂-adrenoceptors in bronchial smooth muscle wall

Receptors are coupled to a G-stimulatory protein

Stimulates the formation of cAMP (cyclic adenosine monophosphate)

cAMP inhibits myosin light chain kinase

MLC phosphorylation leads to cross-bridge formation between the myosin heads and the actin filaments and hence, smooth muscle contraction.

Inhibition of this process prevents contraction of muscle



Side effect

Site	Туре	Effect
Cardiac muscle	beta ₁	Tachycardia Arrhythmia
Vascular smooth muscle	beta ₂	Systemic vasodilation
Skeletal muscle	beta ₂	Fine tremor

Caution

- Can cause hypokalaemia
 - Higher doses
 - **o** In conjunction with corticosteroids / theophylline





Beta Blockers North (for treatment of co-existing heart failure)

- Beta blockers (predominantly cardio-selective) may confer reductions in mortality, exacerbations, and hospital admissions in patients with COPD, in addition to the benefits attributable to addressing cardiovascular risk.
- COPD is not a contraindication to beta blockers
- BMJ (2011) <u>https://www.bmj.com/content/342/bmj.d2549</u>





Muscarinic antagonists

Short acting (SAMA)

- Ipratropium (Atrovent)
 - o (Atrovent® pMDI)
 - o 20 mcg
 - $\,\circ\,$ Two doses, four times daily or as required





Long acting (LAMA)



Inhaler name	Drug name	Frequency	
Spireva [®] handihaler [®]	Tiotropium 18mcg	One dose Once daily	HandiHaler®
Braltus [®] Zonda [®]	Tiotropium 10mcg	One dose Once daily	Zonda
Incruse [®] Ellipta [®]	Umeclidinium 55 mcg	One dose Once daily	Incluse Inclus



vvenbeing tor me

Antimuscarinic - parasympathetic Central and MISS Central and Central and MISS Foundation Trust



Inhibit action of acetylcholine

Prevents increase in intracellular concentration of Calcium ion

Calcium binding required to expose active binding sites on actin for myosin

Prevent bronchoconstriction





Side effects

- Poorly absorbed therefore relatively mild side effects
- Dry mouth
- GI Motility disorder
- Urinary retention

Caution

Ipratropium - Glaucoma





LAMA or LABA?

Both:

- Improved lung function
- Improved dyspnoea
- Improved health status

LAMA:

- Greater effect on exacerbation reduction
- Reduce hospitalisation

Cochrane Review, 2012: Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. <u>https://doi.org/10.1002/14651858.CD009157.pub2</u>



Dual bronchodilator (LABA/LAMA)



Inhaler name	LAMA	LABA	Frequency	
Anoro [®] Ellipta [®]	Umeclidinium	Vilanterol 22	One dose	Reference and a second se
	55 mcg	mcg	Once daily	
Ultibro Breezhaler®	Glycopyrronium 50mcg	Indacaterol 110mcg	One dose Once daily	Ultibro breezhaler 6.vovars
Spiolto [®]	Tiotropium	Olodaterol	Two doses	
Respimat [®]	2.5mcg	2.5mcg	Once daily	
Duaklir®	Aclidinium	Formoterol	One dose	Concentration of the second seco
Genuair	340mcg	12mcg	Twice daily	



Dual bronchodilator (LABA/LAMA)

Compared with other dual therapy combinations and with monotherapy:

- Reduced risk of moderate to severe exacerbations
- Greater improvement in symptoms and QOL scores
- Improved lung function

Cochrane review, 2018: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. <u>https://doi.org/10.1002/14651858.CD012620.pub2</u>

• Most cost-effective option.



Inhaled corticosteroids



- Reduce frequency of exacerbations
- Reduce severity of exacerbations
 - Oral corticosteroids
 - Hospitalisation
- Risk:
 - Pneumonia
 - Local and systemic side effects
- <u>Use for people with features of asthma/steroid</u>
 responsiveness
- <u>Always in combination with LABA</u>

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal 2009 34: 641-647; DOI: 10.1183/09031936.00193908



Combination (ICS / LABA)



Name	ICS	LABA	Frequency	
Fostair [®] pMDI	Beclometasone 100mcg	Formoterol 6mcg	Two doses Twice daily	Territory (
Relvar [®] Ellipta [®]	Fluticasone Furoate 92 mcg	Vilanterol 22 mcg	Once daily	ELEVEL ELEVEL
DuoResp [®] Spiromax [®]	Budesonide 160mcg <u>Or</u> 320mcg	Formoterol 4.5mcg <u>Or</u> 9mcg	Two doses Twice daily <u>Or</u> One dose Twice daily	PuoResp poor Poo Poo
Seretide [®] Accuhaler	Fluticasone propionate 500mcg	Salmeterol 50mcg	One dose Once daily	

Triple therapy


Name	ICS	LAMA	LABA	Frequency	
Trelegy [®] Ellipta [®]	Fluticasone furoate 92mcg	Umeclidinium bromide 55mcg	Vilanterol 22mcg	One dose Once daily	CELEGY DELEGY
Trimbow ®	Beclomethasone fine particle 87mcg	Glycopyrronium 9mcg	Formoterol 5mcg	Two doses Twice daily	



Vvelibeing for life

Inflammatory pathway





Abbreviations: AA, arachidonic acid; PLA₂, phospholipase A₂; PLC, phospholipase C; COX, cyclooxygenase; NSAIDS, non-steroidal antiinflammatory drugs; +, vasoconstriction; –, vasodilation.

https://www.cvphysiology.com



Corticosteroids



Bind to glucocorticoid receptor to form receptor-ligand complex.

Activated complex translocates into the cell nucleus

Causes up-regulation of anti-inflammatory proteins.

Also represses expression of pro-inflammatory proteins in the cytosol by preventing translocation of other transcription factors from the cytosol into the nucleus.


Reduced inflammation in airways

Reduced mucus secretion



Side effects

Central and North West London NHS Foundation Trust







High dose inhaled corticosteroid

 Any patient on long-term high dose ICS (≥ 1000micrograms of standard beclometasone daily or equivalent) should be provided with a High Dose Inhaled Steroid card

High Dose In	haled Corticosteroid Safety Card
Name:	DOB:
I take:	Strength:
MDI + Spacer / A	ccuhaler / Turbohaler /
At a dose of:	puffs time(s) a day
	f corticosteroid insufficiency when I am ill tion should be considered.
	Date:

You have been given this safety card because you are taking a high dose of inhaled corticosteroid.

It is important that you do NOT stop using your inhaled corticosteroid suddenly, particularly if you have been taking this medication for more than 3 weeks.

Be sure to get your repeat prescription of your inhaler before it runs out.

Always carry this card with you and show it to your medical team if you become ill.



https://www.networks.nhs.uk/nhs-networks/london-lungs/documents/inhaledcorticosteroids-in-adults



ICS conversion chart



	Total Daily Dose of Inhaled Corticosteroid			
	Low dose No ICS card required	Intermediate dose Consider an ICS card	High dose ICS card is required	
Beclometasone dipropionate	No 100 Card required	Consider an ico card	ico cara la required	
Aerosol Inhaler (prescribe by brand name)				
Non-proprietary	<800 micrograms	800-1000 micrograms	≥1000 micrograms	
Clenil modulite	<800 micrograms	800-1000 micrograms	≥1000 micrograms	
Qvar (BDP HFA)	<400 micrograms	400-500 micrograms	≥500 micrograms	
Fostair (BDP HFA)	<400 micrograms	400-500 micrograms	≥500 micrograms	
Dry Powder Inhaler				
Asmabec Clickhaler	<800 micrograms	800-1000 micrograms	≥1000 micrograms	
Budesonide				
Dry Powder Inhaler				
Easyhaler, Novolizer	<800 micrograms	800-1000 micrograms	≥1000 micrograms	
Turbohaler (Pulmicort, Symbicort)	<800 micrograms	800-1000 micrograms	≥1000 micrograms	
Ciclesonide				
Aerosol Inhaler Alvesco	≤240 micrograms	320 micrograms	≥480 micrograms	
Fluticasone propionate (FP)				
Aerosol Inhaler				
Flixotide, Flutiform [*] , Seretide	<400 micrograms	400-500 micrograms	≥500 micrograms	
Dry Powder Inhaler				
Flixotide and Seretide	<400 micrograms	400-500 micrograms	≥500 micrograms	
Fluticasone furoate (FF)*				
Dry Powder Inhaler Relvar		Literature not available*		
Mometasone furoate				
Dry Powder Inhaler Asmanex	220 micrograms	440 micrograms	≥880 micrograms	

London Respiratory Network




Device / technique

Inhaler Device Types - The inhaler colour will vary depending on drug content						
Aerosol and Spacer devices "Slow and Steady" inspiration			Dry Powder devices "Quick and Deep" inspiration			
Metered Dose Inhaler	<u>Volumatic</u> ®	<u>Aerochamber</u> ® <u>Plus</u>	<u>HandiHaler</u> ®	<u>Zonda</u> ®	Ellipta®	<u>Spiromax</u> ®
		AeroChamber	HandiHaler"	Zanadar	Contraction of the second seco	
			Inspiratory flow required 30-60L/min	Inspiratory flow required 30- 60L/min	Inspiratory flow required 30-90L/min NB: Anoro® Ellipta® shown above. Relvar Ellipta® has yellow cap. Incruse Ellipta has green cap	Inspiratory flow required 30- 90L/min

- NCL formulary
 - Narrow
 - Based on patient focus groups
 - Ease of use and regime
- Prescribe by BRAND NAME





https://www.haag-streit.com/clement-clarke/products/inhaler-technique/in-check-dial-g16





Choice and competency

UK inhaler group: Inhaler standards and competency document

https://www.respiratoryfutures.org.uk/media/69775/uki g-inhaler-standards-january-2017.pdf

NICE patient decision tool for asthma

https://www.nice.org.uk/guidance/ng80/resources/inhal ers-for-asthma-patient-decision-aid-pdf-6727144573






Acute exacerbation of COPD

- "A sustained worsening of a person's symptoms from their stable state beyond usual day-to-day variations and is acute in onset" (NICE, 2018)
- Exacerbations can be associated with:
 - **o Breathlessness**
 - **o** Sputum purulence
 - Sputum volume
 - o Cough





Management of acute exacerbations







Management of acute exacerbations

- Oral prednisolone 30mg OD for 5 days (NICE, 2019)
 Caution hyperglycaemia
- Only if purulent sputum
 - Add Oral antibiotics
 - Amoxicillin 500mg TDS for 5 days
 - Doxycycline 200mg on day 1 then 100mg OD for 4 further days

https://www.gov.uk/government/publications/managingcommon-infections-guidance-for-primary-care(as Oral antibiotics



Frequent exacerbations



- Secondary care
- Respiratory physiotherapy
- **Prophylactic antibiotic (Azithromycin)**
 - May reduce exacerbation rate
- Mucolytic (Carbocisteine)
 - Reduce viscosity of mucus (Break disulphide bond)
 - May reduce exacerbations in select patient group
- Phosphodiesterase inhibitors (Rofumilast)
 - Reduce inflammation (inhibit breakdown of intracellular cAMP)
 - Severe/Very severe COPD, frequent exacerbations
 - Improved lung function and reduced exacerbations



Other respiratory medications -Insufficient evidence



- Anti-IL-5 monoclonal antibody (Mepolizumab) and Anti-IL-5 receptor-α antibody (Benralizumab)
 - Severe COPD, frequent exacerbations, high eosinophil count
 - Reduces eosinophils
 - Further studies required
- Methylxanthine (Theophylline)
 - Bronchodilator and vasodilator effect
 - Narrow therapeutic index caution with enzyme inducer / inhibitors
- Leukotriene modifier (Montelukast)
 - **o** Reduce inflammatory mediator, inhibit bronchoconstriction



Resources



• NICE

https://www.nice.org.uk/guidance/ng115/resources/chronicobstructive-pulmonary-disease-in-over-16s-diagnosis-andmanagement-pdf-66141600098245

• GOLD

https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20 WMV.pdf

• CCG

https://gps.northcentrallondonccg.nhs.uk/

• BLF

https://www.blf.org.uk/support-for-you/copd

• BTS

https://www.brit-thoracic.org.uk/qualityimprovement/guidelines/home-oxygen/

